Vystar Corp (VYST) 0.0250 $VYST Vystar Focuses on Vytex

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Vystar Corp (VYST) 0.0250 $VYST

Vystar Focuses on Vytex Latex Commodities and Licensing; Exits Sleep Diagnostics
Marketwire Canada - Mon Jun 06, 7:30AM CDT
DURHAM, NC and ATLANTA, GA--(Marketwired - Jun 6, 2016) - Vystar Corp. (OTC PINK: VYST) has closed its Kiron Sleep Lab LLC division in Durham, NC in order to focus on its core business of Vytex® environmentally friendly, ultra low protein natural rubber latex commodities and licensing business.

Vystar Corporate Update: Fast Growing New Latex Commodity, 2016 Guidance
Marketwired - Tue Jan 12, 6:30AM CST
Vystar Corp. (OTC PINK: VYST) CEO and President Bill Doyle recaps 2015 highlights and updates shareholders on Vystar's progress with Vytex(R), the new game changing rubber commodity developed, patented worldwide and owned by Vystar. Vytex has the lowest levels of allergenic proteins of any latex. Currently the proteins in Vytex are undetectable using accepted testing methods, thus not exposing the public. Products manufactured using Vytex versus regular latex have been shown to be stronger and are ecofriendly. Vytex has become the standard to which all other latex products aspire. Vytex has FDA clearances in gloves and condoms, and is being used in many other industries such as bedding and adhesives.

Vystar Appoints Financial Executive Jason Meggs to Board of Directors
Marketwired - Tue Dec 08, 7:28AM CST
Vystar Corporation's (OTC PINK: VYST) Board of Directors has voted to appoint Jason M. Meggs, a CPA and senior finance executive, to the Board of Directors.

Vystar Director Matthan to Unveil Major Advances in Ultra Low Protein Latices at International Latex Conference
Marketwired - Thu Aug 06, 7:25AM CDT
Vystar Corp. (OTC PINK: VYST) Board of Directors Member and Research & Development Director Ranjit K. Matthan, Ph.D., will reveal ongoing developments in the formulation of Ultra Low Protein Latices (ULPL) with reduced or no ammonia and nitrosamines at the International Latex Conference session titled "Advances in Environmentally Friendly Ultra Low Protein Natural Rubber Specialty Latices" at 11:30 a.m., August 12th at the Hilton Akron/Fairlawn in Akron, Ohio. The significant advances in aluminum hydroxide-treated Ultra Low Protein Latices (ULPL) properties and applications are potential game-changers for the issues of volatile organic content and nitrosamines for some critical latex products, such as balloons, catheters, condoms, and other medical devices, as well as enabling cleaner and more sustainable work environments.

Vystar 2014 Financial Highlights: Debt, Loss Reduced; Positioned for New Markets
Marketwired - Thu Apr 23, 7:28AM CDT
Vystar Corp. (OTC PINK: VYST) posted financial results for the 12 months ended December 31, 2014 that included increased revenue and decreased loss. "2014 was a year of cleaning up and rebuilding to position Vystar for the future," stated William Doyle, CEO of Vystar. "We had a small increase in year over year revenue and decreased our loss with the closure of our unprofitable SleepHealth division and the sell off of the SleepHealth assets. We took the opportunity to refocus our efforts in the sleep industry and brought in a new medical director in 2014 who is helping us turn our Kiron Clinical Sleep Lab division around. In addition, we settled three litigation suits, reduced convertible debt by 23 percent and made substantial progress on new product research and development that has positioned Vystar for strategic entry into several new markets. We're already seeing the benefits of the steps we took in 2014 that are translating to improved financial performance in 2015."

Natural Rubber Latex Expert Dr. Ranjit Matthan Joins Vystar Board of Directors
Marketwired - Thu Mar 12, 7:25AM CDT
Ranjit K. Matthan, Ph.D., an internationally renowned latex and rubber expert, has joined Vystar Corporation's (OTC PINK: VYST) Board of Directors. Dr. Matthan has been a consultant to Vystar since 2008 and has played a significant role in the manufacturing scale up of reduced-protein Vytex(R) natural rubber latex (NRL) in Malaysia and refining the research and development of manufacturing processes for applications using Vytex NRL, such as latex foam, condoms, adhesives, medical devices, etc.

Vystar Corporation Names New Acting CFO
Marketwired - Thu Feb 19, 6:55AM CST
Vystar(R) Corp. (OTC PINK: VYST) has named Warren Binderman, CPA, as its acting Chief Financial Officer, effective immediately. Vystar President and CEO, William Doyle previously executed the CFO duties.

Vystar Corp. Awards Rotman-Eisenberg-Led Nature's Home Solutions Exclusive Distribution Rights for Eco-Friendly Vytex(R) NRL Foam
Marketwired - Thu Jan 22, 7:02AM CST
Vystar(R) Corp. (OTC PINK: VYST) has entered an exclusive agreement with Nature's Home Solutions (NHS), a new distribution company led by Steve Rotman and Tom Eisenberg, for U.S. distribution rights of Vystar's Vytex(R) Natural Rubber Latex (NRL) foam. (see related NHS Launch Release) Nature's Home Solutions is devoted to identifying and bringing to market innovative, sustainably sourced, eco-friendly materials and technologies for use in furnishings and other markets. NHS will have exclusive distribution rights to Vytex NRL foam for the U.S. furnishings, homegoods and other markets and non-exclusive distribution rights to Vytex NRL threads for the U.S. apparel industry.

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Championing Change: USTA Mid-Atlantic Gala's Impact

Updated Category News Views 262

A Night to Remember: USTA Mid-Atlantic's Gala Who would've thought tennis could wield such transformative power? This ain't your average sport gala. Last Saturday, a crowd of over 300 gathered at the Ritz-Carlton Tysons Corner for the USTA Mid-Atlantic Foundation's 2026 Tennis Creates Gala. Hosted by the formidable Malika Andrews, this event wasn't just a fancy...

Continue Reading
Viking Ventures: Impacts of VK2735 on Obesity Examined

Updated Category News Views 135

Viking Therapeutics Reveal Surprising Data on VK2735 The latest from Viking Therapeutics' camp is giving obesity some serious food for thought, with new data making waves at the ObesityWeek® 2026 meeting. Their investigational dual agonist, VK2735, seems to be shaking things up, as early phase clinical data shows an impressive 74% of participants managed to improve at...

Continue Reading
EZaccessMD Data Breach: Class Action Lawsuit Looms

Updated Category News Views 718

Data breaches are the bogeyman no one wants lurking in the shadows, and when it’s your personal info at stake, folks rightfully squirm. This recent fiasco at EZaccessMD is one of those unsettling incidents. The word on the street isn't pretty: sensitive medical data has slipped through the cracks, leaving Edelson Lechtzin LLP, a heavyweight in class action maneuvers, to...

Continue Reading
D-Wave Quantum Hit with Securities Fraud Lawsuit

Updated Category News Views 314

A Legal Quagmire for D-Wave Quantum Investors Securities fraud lawsuits are like light in a dark alley—you need them when the truth's been stashed out of sight, but they illuminate the dirty and damp parts of investment strategies nobody wants to talk about. Right now, D-Wave Quantum Inc. is smack dab in the middle of such litigious action. If you had the misfortune of...

Continue Reading
Beef 'O' Brady's Expands Into Tuscaloosa Market

Updated Category News Views 187

A New Player in Town: Beef 'O' Brady's Lands in Tuscaloosa Listen up, sports fans and pub grub lovers of Tuscaloosa! Beef 'O' Brady's just kicked down the doors and expanded its reach, opening a location smack on McFarland Boulevard. The place threw open its doors on October 26 and is set to make waves in the local scene, driven by the dedicated hands of Mitul Patel and...

Continue Reading
Ambrosia Biosciences Unveils Promising Nonclinical Metabolic Data

Updated Category News Views 255

Ambrosia's Latest Nonclinical Revelations Ambrosia Biosciences has just thrown out some major bait at ObesityWeek® 2026. The highlight? New nonclinical data profiles for two of their understudy small molecule programs—AMB-895 and AMB-131. It may sound niche, but in this sector, promising data spins heads. Their GLP-1 receptor agonist, AMB-895, and GIP receptor...

Continue Reading
Pan-Mass Challenge Gifts $80M to Dana-Farber for 2026

Updated Category News Views 63

A Momentous Gift in a Crunch Time for Cancer Research Biking and philanthropy might seem like an odd duo, but let me tell you, the Pan-Mass Challenge (PMC) is making that partnership look like peanut butter and jelly. This year, PMC rolled out a jaw-dropping $80 million gift to the Dana-Farber Cancer Institute. You heard right—eighty million smackeroos. Talk about going...

Continue Reading
IDEAYA's IDE101: A New Front in Cancer Battle

Updated Category News Views 129

IDEAYA's Bold Move in Precision Medicine IDEAYA Biosciences, no stranger to the frontlines of cancer treatment, is gunning for a breakthrough with their latest pick, IDE101. They're jumping into the ring with a potential first-in-class inhibitor targeting CDKN2A-deficiency—a notorious player in the solid tumor game. They're not just mixing things up for the sake of it;...

Continue Reading
InstaHeat 35K: FOGATTI Offers Upgraded RV Furnace Control

Updated Category News Views 287

Winter RV Trips Just Got Cozier There's nothing quite like hitting the open road in an RV during the winter months. But let's face it, nobody wants to return to a cabin that's as frigid as the great outdoors. Here's where FOGATTI steps up its game with the InstaHeat Ultra 35K RV Furnace. They’ve tinkered with the thermostat to iron out more precise control, just in time...

Continue Reading
YONDELIS: Thai Approval Opens New Sarcoma Treatment Path

Updated Category News Views 62

New Hope for Thai Sarcoma Patients Alright, we’ve got some good news coming out of Thailand, folks. The Thai FDA just greenlit YONDELIS® (trabectedin) for those grappling with advanced soft tissue sarcoma (STS). Now, this isn’t your everyday drug release—it’s a clinical chess move packing potential for patients who’ve run out of other options. December 1st,...

Continue Reading

Top 5 Most Recently Viewed Articles

Exploring Kearney's 2025 Global Cities Report Insights

Updated Category News Views 654

Global Cities Adapt to New Challenges and Emergence Global cities hold steady at the top as new hubs surge forward Top cities reaffirm their dominance in the Global Cities Index, showcasing remarkable resilience amidst global changes and uncertainties. The Global Cities Outlook indicates a noticeable shift as traditional leaders face turbulence, while emerging Gulf and...

Continue Reading
Vacca Family Law Group Enhances Support for Peaceful Divorce

Updated Category News Views 255

Empowering Families Through Non-Adversarial Divorce Solutions Families navigating the challenging process of separation now have renewed access to considerate and non-confrontational divorce options. Vacca Family Law Group has recently welcomed Attorney and Mediator Wendy Reimer, who brings nearly two decades of experience in family law and a strong background in...

Continue Reading
Ingredion Delivers Impressive Q3 Results, Upgrades Outlook

Updated Category News Views 55

Ingredion's Strong Performance in the Third Quarter Ingredion Incorporated (NYSE: INGR) has reported remarkable results for the third quarter of 2024, showcasing a noteworthy surge in both operating income and earnings per share (EPS). The global leader in ingredient solutions for the food and beverage industry achieved a stunning 26% increase in reported operating income...

Continue Reading
Insight into Learning Technologies Group Plc's Disclosure Mechanism

Updated Category News Views 193

Understanding the Public Opening Position Disclosure Process In the complex world of financial securities, understanding the disclosure requirements can feel daunting. However, the process outlined by the Takeover Code, particularly Rule 8.3, provides a structured approach for individuals and entities holding significant interests in relevant securities. This rule is...

Continue Reading
Avidity Biosciences Set to Inspire with Latest Presentations

Updated Category News Views 191

Avidity Biosciences' Key Presentations at the MDA Conference Avidity Biosciences, Inc. (Nasdaq: RNA), a pioneer in RNA therapeutics, is poised to make a significant impact at the upcoming Clinical and Scientific Conference organized by the Muscular Dystrophy Association (MDA). The event will showcase the latest advancements in the field and highlight groundbreaking...

Continue Reading